1. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

Anaerobes infection

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-13625
    Ertapenem sodium
    Maximum Cited Publications
    12 Publications Verification

    L-749345; MK-826

    Bacterial Antibiotic Infection Cancer
    Ertapenem sodium (L-749345) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem sodium has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem sodium can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract .
    Ertapenem sodium
  • HY-12479A
    Epetraborole hydrochloride
    2 Publications Verification

    GSK2251052 hydrochloride

    Bacterial Aminoacyl-tRNA Synthetase Infection
    Epetraborole (GSK2251052) hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole hydrochloride can be used in multidrug-resistant gram-negative pathogens infection research .
    Epetraborole hydrochloride
  • HY-A0294

    MK-0826

    Antibiotic Bacterial Infection Cancer
    Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract .
    Ertapenem
  • HY-A0294A
    Ertapenem disodium
    Maximum Cited Publications
    12 Publications Verification

    MK-0826 disodium

    Bacterial Antibiotic Infection Cancer
    Ertapenem (MK-0826) disodium is a broad spectrum and long acting β-lactam antibiotic. Ertapenem disodium has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem disodium can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract .
    Ertapenem disodium
  • HY-13625R

    L-749345 (Standard); MK-826 (Standard)

    Reference Standards Bacterial Antibiotic Infection Cancer
    Ertapenem sodium (Standard) is the analytical standard of Ertapenem sodium. This product is intended for research and analytical applications. Ertapenem sodium (L-749345) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem sodium has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem sodium can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract[1][2].
    Ertapenem sodium (Standard)
  • HY-18324
    CRS3123
    1 Publications Verification

    REP-3123

    Antibiotic Inflammation/Immunology
    CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .
    CRS3123
  • HY-A0035

    Antibiotic Bacterial Infection
    Faropenem is a potent and orally active beta-lactam antibiotic. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral proagent, faropenem medoxomil, for the research of respiratory tract infections .
    Faropenem
  • HY-106882

    MDL 62879

    Bacterial Antibiotic Infection
    GE 2270A (MDL 62879) is an antibiotic. GE 2270A inhibits gram-positive bacteria and anaerobes by inhibiting protein synthesis. GE 2270A can be used for the research of infection .
    GE 2270A
  • HY-12479

    GSK-2251052; AN 3365

    Bacterial Aminoacyl-tRNA Synthetase Infection
    Epetraborole (GSK2251052) is a leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole can be used in multidrug-resistant gram-negative pathogens infection research .
    Epetraborole
  • HY-A0294AR

    MK-0826 disodium (Standard)

    Reference Standards Bacterial Antibiotic Infection Cancer
    Ertapenem (disodium) (Standard) is the analytical standard of Ertapenem (disodium). This product is intended for research and analytical applications. Ertapenem (MK-0826) disodium is a broad spectrum and long acting β-lactam antibiotic. Ertapenem disodium has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem disodium can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract[1][2].
    Ertapenem disodium (Standard)
  • HY-12479B

    GSK-2251052 (R-mandelate); AN 3365 (R-mandelate)

    Bacterial Aminoacyl-tRNA Synthetase Infection
    Epetraborole R-mandelate is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole R-mandelate can be used in multidrug-resistant gram-negative pathogens infection research .
    Epetraborole (R-mandelate)
  • HY-A0294S

    MK-0826-d4

    Isotope-Labeled Compounds Bacterial Antibiotic Infection Cancer
    Ertapenem-d4 (MK-0826-d4) is deuterium labeled Ertapenem. Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract .
    Ertapenem-d4
  • HY-106946

    Bacterial
    E 5065 is an orally active antibacterial agent. E 5065 exhibits potent in vitro activity against Gram-negative microorganisms, Gram-positive cocci, and anaerobes. E 5065 exhibits an MIC90 of 0.5 μg/mL against Clostridium spp. E 5065 provides protection against experimental infections caused by P. aeruginosa .
    E 5065
  • HY-116880

    Bacterial DNA/RNA Synthesis Infection
    DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .
    DS-2969b

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

 

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

 

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: